Table 1.
Characteristics at diagnosis and at TVD therapy of 63 patients with refractory metastatic neuroblastoma after COJEC induction
| Characteristic | No. (%) |
|---|---|
| At diagnosis | |
| Age, median (IQR, mo) | 46 (28-69) |
| Primary tumour site | |
| Abdomen | 55 (87.3) |
| Chest | 6 (9.5) |
| Other | 2 (3.2) |
| Stage 4 | 63 (100) |
| MYCN, amplifieda) | 13 (23.6) |
| At study entry | |
| Overall INRC response post-COJEC | |
| PR | 40 (63.52) |
| MR | 7 (11.1) |
| SD | 15 (23.8) |
| PD | 1 (1.6) |
| Metastatic response post-COJEC | |
| PR | 46 (73.0) |
| SD | 16 (25.4) |
| PD | 1 (1.6) |
| Localization of metastatic disease at TVD entry | |
| Bone marrow only | 10 (15.9)b) |
| Skeleton only | 25 (39.7)c) |
| Combined bone marrow and skeleton | 27 (42.9)b),c) |
| Liver | 1 (1.6) |
TVD, topotecan-vincristine-doxorubicin; IQR, interquartile range; INRC, International Neuroblastoma Response Criteria; PR, partial response; MR, mixed response; SD, stable disease; PD, progressive disease; mIBG, metaiodobenzylguanidine.
a)
Based on 55 evaluable cases,
b)
Total bone marrow positive (n=37),
c)
Total mIBG skeleton positive (n=52).